Methods for the treatment and diagnosis of bone mineral density related diseases
Described herein are methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, described herein are methods of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of such a mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. Also described are compounds such as a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). Additional aspects describe an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).
1. A method for treating a disease associated with a decreased bone mineral density comprising administering to a subject in need thereof a compound selected from the group consisting of a thromboxane synthase inhibitor and a thromboxane receptor antagonist, wherein said disease associated with decreased mineral density is osteogenesis imperfecta.
2. The method of claim 1 , wherein said thromboxane synthase inhibitor or thromboxane receptor antagonist is selected from the group consisting of Ozagrel, Seratrodast and Picotamide.